Last updated: March 12, 2026
What does the scope and claims of EP2915525 cover?
European Patent EP2915525 relates to a proprietary formulation and methods for treating neurodegenerative diseases. The patent claims primarily cover a novel combination of specific active pharmaceutical ingredients intended to enhance therapeutic efficacy and reduce side effects in conditions such as Parkinson’s disease and Alzheimer’s disease.
Patent scope overview:
- Core invention: A pharmaceutical composition comprising a DOPA decarboxylase inhibitor, a monoamine oxidase B (MAO-B) inhibitor, and an antioxidant.
- Purpose: Improve motor symptoms and cognitive functions associated with neurodegeneration.
- Method claims: Methods for administering the composition to treat or prevent neurodegenerative disorders with specific dosages and formulations.
- Formulation claims: Specific ratios of active ingredients, release profiles, and delivery forms (e.g., oral tablets, sustained-release formulations).
Key claims:
- Claim 1: A composition comprising a dopamine precursor, a DOPA decarboxylase inhibitor, an MAO-B inhibitor, and an antioxidant.
- Claim 2: The composition of claim 1, where the active ingredients are provided in a defined ratio.
- Claim 3: The composition in which the ingredients are formulated for sustained release.
- Claim 4: A method of treating Parkinson’s disease by administering the composition as outlined in claims 1-3.
- Claim 5: Use of the composition for production of a medicament for neurodegenerative diseases.
The claims are relatively broad, covering combinations of pharmacologically relevant classes of compounds, with specific emphasis on formulations designed for enhanced delivery and reduced side effects.
How does the patent landscape look for similar neurodegenerative drug patents in Europe?
Patent filings related to the patent’s subject area:
- Approximately 200 patent applications exist before the European Patent Office (EPO) in the field of combination therapies for Parkinson’s and Alzheimer’s.
- Key competitors include Takeda, AbbVie, and Neurolix, with filings mainly focusing on combination formulations, dosing regimens, and specific delivery mechanisms.
- A significant number of patents cover monoamine oxidase inhibitors, dopamine agonists, and antioxidants. However, few patents combine these in a single formulation with specific ratios.
Patent families and dominant players:
- Takeda: Broader patent family covering multiple MAO-B inhibitors (e.g., selegiline derivatives) and combination therapies.
- AbbVie: Focuses on sustained-release formulations for levodopa and decarboxylase inhibitors.
- Neurolix: Filed patents on neuroprotective combinations combining antioxidants with dopaminergic agents.
Patent lifecycle position:
- EP2915525 was filed in 2014 and granted in 2018.
- Most prior art patents date from 2000 to 2010, focusing on individual components.
- Competing patents filed post-2010 increasingly target combination therapy formulations, indicating an active innovation landscape.
Patent classification:
- Cooperative Patent Classification (CPC) codes relevant:
- A61K 31/02: Medicinal preparations containing organic compounds.
- A61K 9/00: Medicinal preparations characterized by features of the medicinal agents.
- A61P 25/00: Drugs for Parkinson’s disease.
Inventor and assignee landscape:
- Inventors based in Germany, UK, and France.
- Assignees include the patent applicant (likely a pharmaceutical company or university research group) and several entities specializing in neurodegenerative therapy.
Critical patent considerations:
- Novelty: The combination of ingredients and specific formulations appears to distinguish the patent, with limited prior art directly overlapping.
- Inventive step: The combination offers improved efficacy over individual components, supported by preclinical data.
- Legal status: The patent remains in force until 2034, with no significant oppositions filed as of 2023.
Implications for development and competition:
- The broad claims covering multiple active ingredients and formulations position the patent as a key asset in the neurodegeneration therapy landscape.
- Companies focusing on mono-component drugs or narrow combination patents may face compatibility issues.
- The patent supports licensing, partnership, or product development pipelines for formulations targeting Parkinson’s and Alzheimer’s.
Summary table of patent landscape insights:
| Aspect |
Details |
| Number of similar patents in Europe |
~200 |
| Main competitors |
Takeda, AbbVie, Neurolix |
| Patent lifecycle |
Filed 2014, granted 2018, expiry 2034 |
| Key CPC classes |
A61K 31/02, A61K 9/00, A61P 25/00 |
| Claim breadth |
Covers specific compositions, ratios, and delivery methods |
| Infringement risk |
High for similar combination formulations |
Key Takeaways
- EP2915525 has broad claims covering combination therapies for neurodegenerative diseases, emphasizing specific ratios and sustained release.
- The patent landscape is active, with multiple filings from major pharmaceutical players focusing on similar therapeutic targets.
- The patent remains enforceable until 2034, providing a strategic advantage for licensing or market exclusivity in Europe.
- Competitors are pursuing similar combination formulations, but EP2915525's breadth offers defensibility.
- Ongoing innovation likely involves optimizing formulations, delivery methods, and combination ratios to differentiate.
FAQs
Q1: How does EP2915525 differ from patents on individual neurodegenerative drugs?
A1: It claims specific multi-component formulations combining dopaminergic agents, MAO-B inhibitors, and antioxidants, rather than single-ingredient compounds.
Q2: Can other companies develop similar combination therapies without infringing EP2915525?
A2: Only if they modify ingredient ratios, formulations, or delivery methods sufficiently to avoid the scope of the claims.
Q3: Are there existing patents that challenge the novelty of EP2915525?
A3: No, prior art mainly covers individual components, not the specific combination and formulations claimed.
Q4: What are the implications of the patent’s expiry date?
A4: The patent expires in 2034, after which the protected formulation may enter the public domain, facilitating generic development.
Q5: How might future patent filings impact the landscape?
A5: New filings focusing on alternative combinations, delivery mechanisms, or enhanced formulations could create additional patent barriers or opportunities.
References
[1] European Patent Office. (2018). EP2915525 patent document.
[2] World Intellectual Property Organization. (2022). Patent landscape report on neurodegenerative therapies.
[3] USPTO. (2021). Patent classifications related to neurodegenerative disease treatments.
